ERR2598282
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 25
- umap1_2d
- -4.979927396
- umap2_2d
- -3.747623096
- umap1_3d
- 3.675344668
- umap2_3d
- 1.494687641
- umap3_3d
- -0.845393307
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.480
- KRAS_SIGNALING_DN+0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- MYOGENESIS+0.250
- UV_RESPONSE_UP+0.180
- INTERFERON_ALPHA_RESPONSE+0.170
- ALLOGRAFT_REJECTION+0.130
- XENOBIOTIC_METABOLISM+0.130
- DNA_REPAIR+0.110
- FATTY_ACID_METABOLISM+0.110
Top 10 suppressed
- G2M_CHECKPOINT-0.550
- TGF_BETA_SIGNALING-0.540
- E2F_TARGETS-0.500
- HEDGEHOG_SIGNALING-0.470
- ANGIOGENESIS-0.450
- MITOTIC_SPINDLE-0.440
- UV_RESPONSE_DN-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- WNT_BETA_CATENIN_SIGNALING-0.360
- MYC_TARGETS_V1-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598271 | fetal | fetal | 0.919 |
| 2 | ERR2598294 | fetal | fetal | 0.910 |
| 3 | ERR2598272 | fetal | fetal | 0.900 |
| 4 | TCGA-E2-A572-01A-13R-A31O-07 | — | B | 0.859 |
| 5 | TCGA-AQ-A54O-01A-11R-A266-07 | — | B | 0.842 |
| 6 | ERR2598340 | fetal | fetal | 0.830 |
| 7 | BS_9DZ253JY | pilocytic astrocytoma | — | 0.824 |
| 8 | SRR1087031 | GTEX | — | 0.821 |
| 9 | SJEPD019_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.820 |
| 10 | ERR2598330 | fetal | fetal | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.080 | Idelalisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.040 | Idelalisib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |